Cooper Companies Toekomstige groei

Future criteriumcontroles 3/6

Cooper Companies zal naar verwachting groeien in winst en omzet met respectievelijk 23% en 7% per jaar. De winst per aandeel zal naar verwachting groeien met 24.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10% zijn.

Belangrijke informatie

23.0%

Groei van de winst

24.1%

Groei van de winst per aandeel

Medical Equipment winstgroei	18.2%
Inkomstengroei	7.0%
Toekomstig rendement op eigen vermogen	10.0%
Dekking van analisten	Good
Laatst bijgewerkt	14 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

BOVESPA:C1OO34 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
10/31/2027	4,907	882	1,012	1,429	2
10/31/2026	4,473	778	703	1,051	13
10/31/2025	4,201	645	626	944	18
10/31/2024	3,903	447	541	816	17
7/31/2024	3,804	359	189	615	N/A
4/30/2024	3,732	340	122	550	N/A
1/31/2024	3,666	291	136	564	N/A
10/31/2023	3,593	294	215	608	N/A
7/31/2023	3,514	275	222	564	N/A
4/30/2023	3,427	288	387	685	N/A
1/31/2023	3,380	375	425	693	N/A
10/31/2022	3,308	386	450	692	N/A
7/31/2022	3,219	431	524	736	N/A
4/30/2022	3,139	948	487	696	N/A
1/31/2022	3,029	939	541	757	N/A
10/31/2021	2,923	2,945	524	739	N/A
7/31/2021	2,845	2,916	526	782	N/A
4/30/2021	2,660	2,355	414	671	N/A
1/31/2021	2,465	2,249	207	505	N/A
10/31/2020	2,431	238	176	487	N/A
7/31/2020	2,441	278	180	468	N/A
4/30/2020	2,542	343	234	552	N/A
1/31/2020	2,672	454	459	741	N/A
10/31/2019	2,653	467	421	713	N/A
7/31/2019	2,613	446	499	750	N/A
4/30/2019	2,594	427	561	788	N/A
1/31/2019	2,571	366	523	745	N/A
10/31/2018	2,533	140	-630	669	N/A
7/31/2018	2,443	128	-656	631	N/A
4/30/2018	2,339	131	N/A	551	N/A
1/31/2018	2,230	175	N/A	511	N/A
10/31/2017	2,139	373	N/A	594	N/A
7/31/2017	2,096	345	N/A	588	N/A
4/30/2017	2,055	329	N/A	562	N/A
1/31/2017	2,016	298	N/A	529	N/A
10/31/2016	1,967	274	N/A	510	N/A
7/31/2016	1,904	250	N/A	421	N/A
4/30/2016	1,851	207	N/A	388	N/A
1/31/2016	1,801	194	N/A	401	N/A
10/31/2015	1,797	204	N/A	391	N/A
7/31/2015	1,810	198	N/A	439	N/A
4/30/2015	1,780	241	N/A	450	N/A
1/31/2015	1,758	259	N/A	466	N/A
10/31/2014	1,718	270	N/A	455	N/A
7/31/2014	1,661	296	N/A	453	N/A
4/30/2014	1,640	297	N/A	448	N/A
1/31/2014	1,611	293	N/A	437	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei C1OO34 ( 23% per jaar) ligt boven de spaarquote ( 10.4% ).

Winst versus markt: De winst van C1OO34 ( 23% per jaar) zal naar verwachting sneller groeien dan de BR markt ( 12.8% per jaar).

Hoge groeiwinsten: De winst van C1OO34 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van C1OO34 ( 7% per jaar) zal naar verwachting langzamer groeien dan de markt BR ( 7.5% per jaar).

Hoge groei-inkomsten: De omzet van C1OO34 ( 7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen C1OO34 zal naar verwachting over 3 jaar laag zijn ( 10 %).

Cooper Companies Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

The Cooper Companies, Inc. Raises Earnings Guidance for the Fourth Quarter and Fiscal Year 2024

The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. Raises its Revenue Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. Provides Revenue Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. Updates Revenue Guidance for the Year 2023

The Cooper Companies, Inc. Provides Revenue Guidance for the Year 2023

Recent updates

The Cooper Companies, Inc. to Report Q4, 2024 Results on Dec 05, 2024

The Cooper Companies, Inc. Raises Earnings Guidance for the Fourth Quarter and Fiscal Year 2024

The Cooper Companies, Inc. to Report Q3, 2024 Results on Aug 28, 2024

The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. to Report Q2, 2024 Results on May 30, 2024

The Cooper Companies, Inc. Raises its Revenue Guidance for the Fiscal Year 2024

Girard Sharp LLP and Sauder Schelkopf LLC Files Lawsuit Against Coopersurgical, Inc. and the Cooper Companies, Inc

The Cooper Companies, Inc. Announces Resignation of Gary S. Petersmeyer from Board of Directors

Slater Vecchio LLP Files Class Action Lawsuit Against LifeGroup Global LLC, The Cooper Companies Inc, CooperSurgical Inc, and CooperSurgical Canada Inc

Slater Vecchio LLP Files Class Action Lawsuit Against LifeGroup Global LLC, The Cooper Companies Inc, CooperSurgical Inc, and CooperSurgical Canada Inc

The Cooper Companies, Inc. to Report Q1, 2024 Results on Feb 29, 2024

The Cooper Companies, Inc., Annual General Meeting, Mar 19, 2024

The Cooper Companies, Inc. Announces Retirement of Gary S. Petersmeyer as Director

The Cooper Companies, Inc. Provides Revenue Guidance for the Fiscal Year 2024

CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors, Effective December 1, 2023

The Cooper Companies, Inc. to Report Q4, 2023 Results on Dec 07, 2023

The Cooper Companies, Inc. (NasdaqGS:COO) acquired Bakri Postpartum Balloon, Cervical Ripening Balloon, Doppler Blood Flow Monitor portfolio and gynecology surgery markets of Cook Medical Incorporated for $300 million.

The Cooper Companies, Inc. Updates Revenue Guidance for the Year 2023

The Cooper Companies, Inc. Provides Revenue Guidance for the Year 2023

The Cooper Companies, Inc. to Report Q1, 2023 Results on Mar 02, 2023

The Cooper Companies, Inc., Annual General Meeting, Mar 15, 2023

CooperCompanies Declares Cash Dividend, Payable on February 10, 2023

The Cooper Companies, Inc. Initiates Earnings Guidance for the Fiscal Year 2023

The Cooper Companies, Inc. to Report Q4, 2022 Results on Dec 08, 2022

the Cooper Companies, Inc. Appoints Cynthia Lucchese to Board of Directors

the Cooper Companies, Inc. Updates Revenue Guidance for Fourth Quarter and Full year 2022

the Cooper Companies, Inc. Updates Revenue Guidance for Fourth Quarter and Full Year Year 2022

CooperCompanies Appoints Nicholas Khadder as Its General Counsel and Corporate Secretary

The Cooper Companies, Inc. to Report Q3, 2022 Results on Aug 31, 2022

CooperCompanies Declares Semi-Annual Cash Dividend, Payable on August 11, 2022

The Cooper Companies, Inc. Provides Consolidated Earnings Guidance for the Third Quarter, Fourth Quarter and Full Year of Fiscal 2022

The Cooper Companies, Inc. Provides Revenue Earnings Guidance for the Fiscal Year 2022

The Cooper Companies, Inc. (NYSE:COO) signed a binding letter of intent to acquire Reproductive Health Business of Cook Medical for $880 million.

The Cooper Companies, Inc. to Report Q1, 2022 Results on Mar 03, 2022

The Cooper Companies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

The Cooper Companies, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of Fiscal 2021

CooperCompanies Announces MiSight® Approval from Chinese National Medical Products Administration

The Cooper Companies, Inc.(NYSE:COO) dropped from Russell 1000 Growth-Defensive Index

the Cooper Companies, Inc. Provides Earnings Guidance for the Fiscal Year 2021

The Cooper Companies, Inc. to Report Q1, 2021 Results on Mar 04, 2021

EssilorLuxottica Société anonyme (ENXTPA:EL) and The Cooper Companies, Inc. (NYSE:COO) agreed to acquire SightGlass Vision from The Cooper Companies, Inc. (NYSE:COO).

CooperCompanies Announces Board Changes

The Cooper Companies, Inc. Votes to Elect Teresa S. Madden to Fill the New Director Position, with Effect from December 1, 2020

The Cooper Companies, Inc. to Report Q4, 2020 Results on Dec 03, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven